I wanted to understand not just the science, but how a biotechnology company operates and makes decisions.
Scott Yoder applied to the program because he saw it as a perfect match between science, law and business.
“I wanted to become more familiar with the business side of biotech, its legal aspects, clinical and regulatory strategies. The challenges associated with a startup company, in particular, require a breadth that goes so far beyond a traditional M.S. or M.B.A. degree.”
Mergers and acquisitions—I was living it.
Learning about business strategies, mergers and acquisitions in the program was somewhat serendipitous for Yoder. “Talk about timing and the usefulness of hands-on information—I was living it while I was in graduate school.” Two of his consecutive employers, PowderJect Vaccines, Inc., and then Bone Care International, were purchased and relocated within a span of two years. The degree gave him the skills, not to mention confidence, to use each acquisition and downsize as an opportunity for career advancement. Following the sale of the latter, Yoder advanced into a position as Operations Manager at Stratatech Corporation, Inc., a biotechnology manufacturing company with about 30 employees.
“The biotechnology industry is unique for the variety within its pace of change…the science and technology changes so quickly, but the path to the marketplace is a long, often delayed, one. The program’s courses in technology transfer topics were invaluable to me in learning how to get products to the marketplace…whether in a small start-up company based on university research, or a global pharmaceutical company.”
Time and effort pays off.
The mobility and value of his degree was tested again when Yoder was recruited by Hospira, Inc. in fall 2007. Hospira, a global specialty pharmaceutical and medication delivery company, reintroduced him to the world of big-pharma. From 2007 to 2012, Yoder excelled within Hospira’s global pharmaceutical services division, first as a senior project manager with their contract biomanufacturing operations, then later as member of their global expansion business development team.
Most recently, Yoder again pursued a greater leadership opportunity by accepting a position at Takeda Pharmaceuticals as the Associate Director of Vaccine Business Operations, and later, as Director of Program Management with Chicago-based Melinta Theraeutics. His increasing business experience and breadth of scientific knowledge within the field of biotechnology has made him an attractive hire by any company.
“The courses in the M.S. in Biotechnology were the most applied I have ever taken…that direct application has been incredibly valuable to me as I have moved into different business environments, where a lot of concepts are shared, if you can identify the common factors. The program definitely gave me a competitive advantage in pursuing career and salary progression.”
This is an accordion element with a series of buttons that open and close related content panels.
Questions about the M.S. in Biotechnology Program?
About the M.S. in Biotechnology, UW-Madison
Established in 2002, the Master of Science in Biotechnology at UW-Madison is a two-year cross-disciplinary program for scientists, technical professionals, business strategists and attorneys seeking to advance their career in the biotechnology industry without having to put their career on hold.
The project-based curriculum focuses on the development and commercialization of new technologies and provides a diverse mix of science, business, bioethics, regulatory policy and patent law.
Students are instructed by world-renowned scholars and leading industry professionals in the biotechnology field. Graduates join a powerful professional network of over 350 alumni.